Novartis and Blackstone Life Sciences Collaborate to Launch Anthos Therapeutics for Cardiovascular Disorders
Shots:
- Novartis to get minority equity in Anthos and will grant rights to Anthos for MAA868 to develop in CVD. Blackstone Life Sciences to fund the joint venture with $250M and will take care of development of all products
- The focus of the agreement is to build a joint venture i.e Anthos Therapeutics developing anti-thrombotic therapies for patients with high-risk cardiovascular disorders
- Novartis’ MAA868 is a mAb with anti- Factor XI / XIa involved in prevention of thrombotic disorders with minimal or no bleeding risk
Ref: Anthos Therapeutics | Image: Anthos Therapeutics
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com